Safety and immunogenicity of the LC16m8 vaccine against mpox during outbreak deployment in Colombia: a hybrid, multicentre, open-label, randomised controlled trial and observational cohort study
Year: 2026
Type: article
Study design: Clinical Trial
Abstract: BACKGROUND: LC16m8 is a live-attenuated, replication-competent vaccinia vaccine, but clinical evidence on its efficacy against mpox remains limited. We assessed its efficacy and safety in adults at increased risk of mpox in Colombia. METHODS: We conducted a hybrid study comprising a multicentre, open-label, randomised delayed-vaccination trial and an observational cohort at three centres in Bogotá. Adults aged 18-50 years were randomised 1:1 using stratified permuted blocks to receive one percutaneous dose of LC16m8 at enrolment (Day 0) or on Day 42. The primary outcome was PCR-confirmed mpox during the arm-specific efficacy-assessment windows, analysed in the per-protocol efficacy population; no efficacy outcomes were imputed. Safety outcomes were assessed through Day 180. CLINICALTRIALS: govNCT06223919; retrospectively registered; trial closed to recruitment. FINDINGS: Between December 16, 2023, and January 6, 2024, 208 participants were enrolled and 204 randomised (104 immediate; 100 delayed); 203 were male and one female. The trial randomised 204 of 8686 planned participants. No PCR-confirmed mpox cases occurred in the primary per-protocol efficacy analysis (0/97 immediate vs 0/69 delayed); therefore, the prespecified hazard ratio, 95% CI, p value, and vaccine efficacy were not estimable. Through Day 180, at least one adverse event was reported by 96/98 (98·0%) participants in the immediate-vaccination group and 68/69 (98·6%) in the delayed-vaccination group. One serious adverse event occurred in each group; both were unrelated to vaccination and resolved. No deaths or adverse-event-related study discontinuations occurred. INTERPRETATION: Substantial under-recruitment and the absence of primary outcome events precluded estimation of LC16m8 efficacy. The randomised safety findings were limited by the small sample size. FUNDING: Japan Agency for Medical Research and Development (AMED; JP22fk0108503h0001); Ministry of Health and Social Protection of Colombia; Universidad Nacional de Colombia; National Institute of Health of Colombia.
Source: EBioMedicine
Authors: Carlos Arturo Álvarez-Moreno, Naoki Tomotsugu, Hernando Gaitán-Duarte, Jorge Alberto Cortés, Akira Ainai, Carlos Hernando Gómez, Mieko Hamana, Sandra Liliana Valderrama-Beltrán, Sohtaro Mine, Otto Sussman, Milagros Virhuez-Mendoza, Johana Hernández, Shiori Ueno, Jaime Castellanos, Luz Mery González, María José Amaya, María del Mar Bautista-González, Laura Cristina Nocua-Báez, Mugen Ujiie, Norio Ohmagari, Tadaki Suzuki, Ken Maeda, Yasukata Ohashi, Claudia Marcela Castro-Osorio, Susana Novoa-Herrán, Diego Alejandro Álvarez-Díaz, Gloria Mercedes Puerto, Alejandra M. Muñoz-Suárez, Valentina Guevara-Prieto
Language: English
Subfield: Virology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $5,780
OpenAlex ID: W7226011544
